GlassScriptPhysician profile
Roger A Breslow
NPI 1891782942
$759.01
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $88.66 · 2021: $221 · 2022: $15.74.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $354.96 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $88.00 | 2019-2021 | |
| Octapharma USA, INC. | $68.16 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $49.89 | 2019 | |
| Genzyme Corporation | $49.44 | 2019-2020 | |
| Grifols USA, LLC | $38.54 | 2021 | |
| Pharming Healthcare, INC. | $29.57 | 2021 | |
| Therapeuticsmd, INC. | $21.61 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.74 | 2022 | |
| Novo Nordisk INC | $13.98 | 2019 | |
| Merck Sharp & Dohme LLC | $11.12 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Breslow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.